Navigation Links
Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
Date:4/14/2008

une mediated diseases.

"These data, along with the additional results reported at AACR with our other drug candidates, demonstrate the breadth of our product portfolio," said Richard A. Miller, M.D., president and CEO of Pharmacyclics.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

NOTE: Other than statements of historical fact, the statements made in this press release about enrollment and future plans for our clinical trials, progress of and reports of results from preclinical and clinical studies, clinical development plans and product development and corporate partnering activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "project," "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. The forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with unexpected delays in clinical trials and preclinical studies and the timing for making related regulatory filings; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
3. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
4. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
5. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
6. Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea
7. Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R)
8. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
9. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
10. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
11. Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2008)...tudy finds the majority of acute lymphoblastic leu...ent at the time of diagnosis , , MEMPHIS, T...s at St. Jude Children,s Research Hospital have id... cells of children with acute lymphoblastic leukem...pathway to designing treatments for ALL relapse in...
(Date:11/26/2008)... Expanded to 406 Subjects , , FRANKLIN, Mas...Inc. (OTC Bulletin Board: PLCSF) announced today t...od and Drug Administration (FDA) for its U.S. pivo...y,s RenalGuard System(TM) and associated therapy ...(CIN). , , The FDA also approved PLC,s requ...
(Date:11/25/2008)...ts reveal most respondents against expanding stati... , LITTLE FALLS, N.J., Nov. 25 ...may lower the cardiovascular risk of healthy patie... statin use in older adults, according to a nation...12 participants took part in the online poll condu...
(Date:11/25/2008)...VALE, Calif., Nov. 25 Ph...ed that the company has completed a Phase 1,clini...st-in-class,small-molecule Factor VIIa inhibitor....volunteers to evaluate the safety and pharmacologi... PCI-27483 resulted in a linear dose,response in ...
Breaking Medicine Technology:St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Study shows autism symptoms can improve into adulthood 2104 1Study shows autism symptoms can improve into adulthood 2104 2Possible safer target for anti clotting drugs found 2102 1Possible safer target for anti clotting drugs found 2102 2Thomson Healthcare Endorsed as Preferred Vendor of Information Products and Services for Virginia Hospitals 2100 1Thomson Healthcare Endorsed as Preferred Vendor of Information Products and Services for Virginia Hospitals 2100 2Thomson Healthcare Endorsed as Preferred Vendor of Information Products and Services for Virginia Hospitals 2100 3AAHFNs 2008 Annual Meeting in Boston Will Be Raising the Bar in Heart Failure Care 2098 1AAHFNs 2008 Annual Meeting in Boston Will Be Raising the Bar in Heart Failure Care 2098 2
...is of Phase III trial data underlines M6G,s,benefi...erative,pain , CAMBRIDGE, England, 7th March 2007 ...dge based biopharmaceutical company today,announce... (M6G022),of M6G (morphine-6-glucuronide) in over ...nary data released on 20th February,showed that M6...
...ility of Higher Doses to Further Reduce Antibodies... /PRNewswire-FirstCall/ -- La Jolla,Pharmaceutical...,results from its ongoing double-blind, placebo-co...betimus sodium), its drug,candidate for systemic l... interim antibody data indicate that patients trea...
Other Medicine Technology:CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G 2CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G 3CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G 4CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G 5CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G 6CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G 7La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 7
(Date:12/1/2008)... a cold December day in,Memphis, Tennessee and Fe...amilo Villegas and LPGA star Morgan Pressel have g...s that has brought three of the biggest names in,...e important than any game of,golf -- children bat...m.com/cgi-bin/prnh/20081201/CLM117 ) , Sin...
(Date:12/1/2008)...d Over Prior Year Quarter --, -- Fully I... and Sharpened Commercial Fo... , RICHMOND, BC, Dec. 1 /PRNewswire-FirstCall/...lar device company, today announced financial resu...ptember 30, 2008. , Neovasc Chief Executive Off...
(Date:12/1/2008)...ene repressors for anticancer therapy , Michel...ing Cancer Center, New York, have developed a new ...herapeutic purposes, and used this to mediate effe...ding RNA molecules known as miRNAs are powerful na... the miRNA miR-181a was harnessed to segregate exp...
(Date:12/1/2008)... ViroPharma Incorporated,(Nasdaq: VPHM ) today ...l,Biologics License Application (sBLA) to the U.S...TM) C1 Inhibitor (human) as a treatment for acute ...The sBLA is based on a re-analysis and resubmissio...study of Cinryze and interim data from an ongoing ...
Breaking Medicine News(10 mins):Health News:More than 1,500 Eagles -- Each One with a Story: Eagles Made During PGA TOUR and LPGA Season Result in Record Donation to St. Jude 2Health News:More than 1,500 Eagles -- Each One with a Story: Eagles Made During PGA TOUR and LPGA Season Result in Record Donation to St. Jude 3Health News:More than 1,500 Eagles -- Each One with a Story: Eagles Made During PGA TOUR and LPGA Season Result in Record Donation to St. Jude 4Health News:More than 1,500 Eagles -- Each One with a Story: Eagles Made During PGA TOUR and LPGA Season Result in Record Donation to St. Jude 5Health News:More than 1,500 Eagles -- Each One with a Story: Eagles Made During PGA TOUR and LPGA Season Result in Record Donation to St. Jude 6Health News:More than 1,500 Eagles -- Each One with a Story: Eagles Made During PGA TOUR and LPGA Season Result in Record Donation to St. Jude 7Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 2Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 3Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 4Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 5Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 6Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 7Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 8Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 9Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 10Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 11Health News:JCI online early table of contents: Dec. 1, 2008 2Health News:JCI online early table of contents: Dec. 1, 2008 3Health News:JCI online early table of contents: Dec. 1, 2008 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 5
... even after they stop smoking, says a new study, c...ase ceases when smoking ceases . The new finding i...ease with bronchial inflammation, it will continue...moking. This comes from an international team of ...
...sia's largest healthcare groups, Tuesday launched ...ty in Asia . Going beyond the realm of curative c...cility offering solutions across the healthcare sp...ic medicine, research, information technology and ...
...i generic medicines group Teva to resume deliverie...t by Novartis, the Swiss pharmaceutical group said...ey rejected on Monday a request from Novartis to s...of generic versions of the drug, pending a trial i...
...at has helped thousands of disabled worldwide to w...s first centre on foreign soil . The Colombian gov...g Sahayata Samiti (BMVSS), producers of the artifi...th American country. The BMVSS has entered into a ...
Other Medicine News:Health News:Apollo Sets Up Asia's First Health City in Hyderabad 2Health News:Jaipur Foot All Set to Launch Its Centre in Columbia 2
...ange of miniTHERM incubators is available, ensurin...n solution for their specific requirements. miniTH...ompact and extremely space saving. Their size corr... It is possible to stack up to three units on top ...
In microbiological laboratories and for in vitro fertilization, as well as in cancer research or tissue engineering, the Heraeus CO2 incubator BBD 6220 provides the best contamination protection and
IR Autoflow Dual Chamber Over-Under Water-Jacketed CO 2 Inc.
US Autoflow Single Chamber Stackable Water-Jacketed CO2/O2 Inc.
Medicine Products: